Preliminary Effects of Risk-adapted PSA Screening for Prostate Cancer After Integrating PRS-specific and Age-specific Variation

Overview

Journal Front Genet

Date 2024 Aug 16

PMID 39149591

Authors

Xiaomin Liu

Hongyuan Duan

Siwen Liu

Yunmeng Zhang

Yuting Ji

Yacong Zhang

Zhuowei Feng

Jingjing Li

Ya Liu

Ying Gao

Xing Wang

Qing Zhang

Lei Yang

Hongji Dai

Zhangyan Lyu

Fangfang Song

Fengju Song

Yubei Huang

Affiliations

Soon will be listed here.

Abstract

Background: Although the risk of prostate cancer (PCa) varies across different ages and genetic risks, it's unclear about the effects of genetic-specific and age-specific prostate-specific antigen (PSA) screening for PCa.

Methods: Weighed and unweighted polygenic risk scores (PRS) were constructed to classify the participants from the PLCO trial into low- or high-PRS groups. The age-specific and PRS-specific cut-off values of PSA for PCa screening were determined with time-dependent receiver-operating-characteristic curves and area-under-curves (tdAUCs). Improved screening strategies integrating PRS-specific and age-specific cut-off values of PSA were compared to traditional PSA screening on accuracy, detection rates of high-grade PCa (Gleason score ≥7), and false positive rate.

Results: Weighted PRS with 80 SNPs significantly associated with PCa was determined as the optimal PRS, with an AUC of 0.631. After stratifying by PRS, the tdAUCs of PSA with a 10-year risk of PCa were 0.818 and 0.816 for low- and high-PRS groups, whereas the cut-off values were 1.42 and 1.62 ng/mL, respectively. After further stratifying by age, the age-specific cut-off values of PSA were relatively lower for low PRS (1.42, 1.65, 1.60, and 2.24 ng/mL for aged <60, 60-64, 65-69, and ≥70 years) than high PRS (1.48, 1.47, 1.89, and 2.72 ng/mL). Further analyses showed an obvious interaction of positive PSA and high PRS on PCa incidence and mortality. Very small difference in PCa risk were observed among subgroups with PSA (-) across different age and PRS, and PCa incidence and mortality with PSA (+) significantly increased as age and PRS, with highest risk for high-PRS/PSA (+) in participants aged ≥70 years [HRs (95%CI): 16.00 (12.62-20.29) and 19.48 (9.26-40.96)]. The recommended screening strategy reduced 12.8% of missed PCa, ensured high specificity, but not caused excessive false positives than traditional PSA screening.

Conclusion: Risk-adapted screening integrating PRS-specific and age-specific cut-off values of PSA would be more effective than traditional PSA screening.

References

Oesterling J, Jacobsen S, Chute C, Guess H, Girman C, Panser L . Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993; 270(7):860-4. View

Martin R, Donovan J, Turner E, Metcalfe C, Young G, Walsh E . Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. JAMA. 2018; 319(9):883-895. PMC: 5885905. DOI: 10.1001/jama.2018.0154. View

Shoaibi A, Rao G, Cai B, Rawl J, Haddock K, Hebert J . Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer. Prostate. 2016; 77(2):173-184. DOI: 10.1002/pros.23258. View

Gudmundsson J, Sigurdsson J, Stefansdottir L, Agnarsson B, Isaksson H, Stefansson O . Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nat Commun. 2018; 9(1):4568. PMC: 6224563. DOI: 10.1038/s41467-018-06920-9. View

Gohagan J, Prorok P, Hayes R, Kramer B . The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2001; 21(6 Suppl):251S-272S. DOI: 10.1016/s0197-2456(00)00097-0. View

Conti D, Darst B, Moss L, Saunders E, Sheng X, Chou A . Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021; 53(1):65-75. PMC: 8148035. DOI: 10.1038/s41588-020-00748-0. View

Benafif S, Kote-Jarai Z, Eeles R . A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). Cancer Epidemiol Biomarkers Prev. 2018; 27(8):845-857. PMC: 6051932. DOI: 10.1158/1055-9965.EPI-16-1046. View

Roobol M . Words of wisdom. Re: Mortality results from a randomized prostate- cancer screening Trial. Eur Urol. 2009; 55(6):1481-2. DOI: 10.1016/j.eururo.2009.03.085. View

Nadler R, Humphrey P, Smith D, Catalona W, Ratliff T . Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995; 154(2 Pt 1):407-13. DOI: 10.1097/00005392-199508000-00023. View

10.

Lin S, Brown D, Machiela M . LDtrait: An Online Tool for Identifying Published Phenotype Associations in Linkage Disequilibrium. Cancer Res. 2020; 80(16):3443-3446. PMC: 7442674. DOI: 10.1158/0008-5472.CAN-20-0985. View

11.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

12.

Seibert T, Fan C, Wang Y, Zuber V, Karunamuni R, Parsons J . Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ. 2018; 360:j5757. PMC: 5759091. DOI: 10.1136/bmj.j5757. View

13.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

14.

Mucci L, Hjelmborg J, Harris J, Czene K, Havelick D, Scheike T . Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA. 2016; 315(1):68-76. PMC: 5498110. DOI: 10.1001/jama.2015.17703. View

15.

Kachuri L, Hoffmann T, Jiang Y, Berndt S, Shelley J, Schaffer K . Genetically adjusted PSA levels for prostate cancer screening. Nat Med. 2023; 29(6):1412-1423. PMC: 10287565. DOI: 10.1038/s41591-023-02277-9. View

16.

Matti B, Zargar-Shoshtari K . Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population. Int J Urol. 2021; 28(5):578-583. DOI: 10.1111/iju.14519. View

17.

Sipeky C, Talala K, Tammela T, Taari K, Auvinen A, Schleutker J . Prostate cancer risk prediction using a polygenic risk score. Sci Rep. 2020; 10(1):17075. PMC: 7553910. DOI: 10.1038/s41598-020-74172-z. View

18.

Wallner L, Frencher S, Hsu J, Chao C, Nichol M, Loo R . Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population. BJU Int. 2013; 111(8):1245-52. DOI: 10.1111/j.1464-410X.2012.11651.x. View

19.

Orsted D, Bojesen S, Kamstrup P, Nordestgaard B . Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality. Eur Urol. 2013; 64(3):384-93. DOI: 10.1016/j.eururo.2013.01.028. View

20.

Kim M, Naidoo D, Hazra U, Quiver M, Chen W, Simonti C . Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa. Genome Biol. 2022; 23(1):194. PMC: 9472407. DOI: 10.1186/s13059-022-02766-z. View